North America dominates the global market for epilepsy therapeutics due to increasing prevalence of epilepsy cases in the region. Moreover, increased awareness about the neurological disorders and improved healthcare facilities are driving the market for epilepsy therapeutics in North America. The market for epilepsy therapeutics in Asia is expected to experience high growth rate, followed by that in Europe over the next few years. China and India are expected to be the fastest growing epilepsy therapeutics markets in the Asia. This is due to the large population base and increasing prevalence of epilepsy cases in these countries. Some of the key driving factors of the epilepsy therapeutics market in developing countries are increasing awareness for different neurological disorders and improved healthcare facilities in these regions.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/4126
Increased awareness and technological advancement in field is fuelling the global epilepsy therapeutics market. Moreover, government initiatives in the field are also driving this market. However, factors such as lack of awareness about the condition some developing regions and reluctance to adopt epilepsy medications in some regions are restraining the growth of the epilepsy therapeutics market.
Growing demographics and rising economies of developing countries such as India and China are expected to offer good opportunities for the global epilepsy therapeutics market. Furthermore, innovation of new treatment products with better efficiency is expected to further drive this market. Rising number of mergers and acquisitions, new product launches, and increasing number of collaborations and partnerships are some of the latest trends that have been observed in the global epilepsy therapeutics market.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/4126
Some of the major companies involved in the global market for epilepsy therapeutics are Abbott Laboratories, Cephalon, Inc., Novartis AG, Pfizer, Inc., Johnson & Johnson Limited, GlaxoSmithKline plc, Sanofi S.A., Sunovion Pharmaceuticals, Inc., and Valeant Pharmaceuticals International, Inc.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353